Skip to main content

SARomics Biostructures and Vipergen collaborate to offer enhanced drug discovery services

SARomics Biostructures AB and Vipergen ApS announced today a strategic partnership with the goal to offer enhanced hit and lead identification services based on their complementary technology platforms. By combining Vipergen’s DEL screening technologies with SARomics structural biology capabilities, the companies will enhance their drug discovery services by offering expedited hit identification and lead generation.

Vipergen’s high-fidelity DNA encoded library (DEL) screening technologies enable the identification of novel hit compounds by screening 500+ million drug-like molecules in a single tube or in living cells. Structural information involving detailed information about binding sites and binding poses of identified compounds can rapidly be generated by utilizing SARomics Biostructures structural biology capabilities. This combined information will greatly enhance and accelerate subsequent lead generation of identified hit compounds.

“The collaboration with Vipergen will leverage hit identification and lead generation towards challenging targets and accelerate the discovery of novel therapies” commented Björn Walse, Chief Executive Officer of SARomics.

“Vipergen is pleased to enter into a strategic collaboration with SARomics, a recognized leader in the structural biology field whose high-quality proteins meet all requirements for successful DEL screens,” said Nils Hansen, Chief Executive Officer of Vipergen. “We are excited to leverage our collaboration with SARomics to facilitate even better outcomes for Vipergen’s drug discovery clients.”

About SARomics Biostructures AB

SARomics Biostructures, Lund, Sweden provides structural biology and structure-based drug design services to biotech, pharmaceutical, and academic organizations. SARomics has built a global reputation for its structural biology skills and is currently supporting clients in North America, Europe and Japan to pursue their drug discovery objectives. For more information, please visit www.saromics.com.

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the USA, EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

For additional information please contact:

Dr. Björn Walse, CEO
SARomics Biostructures AB
sales@saromics.com

Dr. Nils Jakob Vest Hansen, CEO
Vipergen ApS
info@vipergen.com

Aurigene Pharmaceutical Services Ltd., and Vipergen announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services.

  • The partnership aims to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening a billion+ small-molecule compounds either in a living cell or on a purified drug target protein.
  • By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, the companies will integrate and enhance their end-to-end discovery solution, by offering expedited hit identification.
  • The two companies will also collaborate on advancing DEL technologies.

 

Hyderabad, India, and Copenhagen, Denmark; April 19, 2024: Aurigene Pharmaceutical Services Ltd. (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DEL technologies, entered into a strategic partnership. The collaboration aims to co-market and offer DEL screening technologies to global customers as a standalone service or as an integrated drug discovery service. The two companies will also co-develop new DELs with an emphasis on novel chemical diversity and drug-likeness to further strengthen their service offering.

Vipergen’s high-fidelity DEL screening technologies would be a strategic addition to Aurigene’s existing small molecule discovery capabilities, from compound resynthesis to candidate nomination. With the addition of hit screening capabilities, Aurigene would be able to enhance its Integrated Drug Discovery (IDD) service offering to its global customers.

“The partnership with Vipergen emphasizes our commitment to accelerating innovation and customer-centric approach. The recent launch of Aurigene.AI for small molecules and DEL partnership with Vipergen aim to reduce the hit finding timelines. Vipergen’s proven track record, with more than 90 partnerships with big pharma and biotech companies, and their streamlined hit finding platform, makes Vipergen the ideal strategic partner for us.”, said Akhil Ravi, CEO, Aurigene.

“We are excited to partner with Aurigene, a global CRDMO focused on customer service. Aurigene’s drug discovery capabilities and global reach makes a perfect match for Vipergen. I am looking forward to a successful partnership, and to offering our proprietary technologies to global customers.”, said Nils Jakob Vest Hansen, PhD, CEO, Vipergen.

 

About Aurigene

Aurigene, a Dr. Reddy’s Laboratories company, is a global contract research, development, and manufacturing organization (CRDMO built on the legacy of accelerating innovation and backed by a vast experience in drug discovery, development, and manufacturing of small and large molecules. We offer integrated and standalone services for discovery chemistry, biotherapeutics discovery, discovery biology, development and manufacturing services for clinical phase I-III programs, regulatory submission batches and commercial manufacturing.

For more details about Aurigene, please visit www.aurigeneservices.com.

LinkedIn YouTube

 

About Vipergen

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan.

For more details about Vipergen and the YoctoReactor® (yR)Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

 

Contacts:

Aurigene

ContactAPSL@aurigeneservices.com

 

Vipergen

info@vipergen.com

 

Vipergen and LEO Pharma Partner for DNA Encoded Library (DEL)-Based Drug Discovery for Dermatology Indications

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications.

Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new in-living-cell DEL platform, to discover novel small-molecule compounds that bind to selected LEO Pharma targets. LEO Pharma will select hits for potential development into innovative drugs for dermatology applications. LEO Pharma will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.

“Driving our mission to rapidly bring better treatments to people with skin conditions, we continue to explore ways to discover novel small-molecule compounds for innovative and challenging targets while shortening development timelines,” said Thorsten Thormann, Vice President of Research & Early Development at LEO Pharma. “Partnering with Vipergen gives us access to the only technology capable of screening DEL libraries inside living cells, under physiologically relevant conditions. We look forward to a productive partnership.”

“We are very pleased to partner with LEO Pharma in its mission to develop first-in-class and best-in-class treatments for the millions of patients around the world suffering with psoriasis, eczema, acne, skin infections, and other serious skin conditions,” said Nils Hansen, PhD, Chief Executive Officer of Vipergen. “We look forward to applying our full suite of DEL screening technologies to accelerate and advance LEO Pharma’s efforts to discover novel, high-quality small molecules for development into innovative new treatments.”

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Contact:

Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com

Vipergen Establishes DNA Encoded Library (DEL)-Based Drug Discovery Partnership with Theseus Pharmaceuticals Focused on Targeted Cancer Therapies

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a drug discovery agreement with Theseus Pharmaceuticals, a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies. Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target. Theseus will select hits for potential development into targeted tyrosine kinase inhibitors (TKIs) and will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.

“Screening small-molecule libraries inside living cells — in a physiologically relevant context — is particularly important for success in developing cancer therapeutics,” said Nils Hansen, PhD, Chief Executive Officer of Vipergen. “We are excited to apply our in-living-cell DEL screening technology to Theseus’ efforts to develop next-generation kinase inhibitors to transform the way cancer is treated.”

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Contact:
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com

Vipergen Establishes Research Partnership with Bayer to Discover Novel Compounds for Pharmaceuticals and More Sustainable Crop Protection Solutions

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target research agreement with Bayer to discover novel small-molecule lead compounds for development of pharmaceuticals and more sustainable crop protection solutions. Under the terms of the agreement, Vipergen will apply its new in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to selected Bayer protein targets. Bayer will select potential drug and crop protection development candidates based on the hits generated by Vipergen’s technology. Bayer will retain exclusive rights to globally commercialize all products resulting from the collaboration. Financial details of the partnership were not disclosed.

Vipergen’s Cellular Binder Trap Enrichment® (cBTE) technology is the first and only platform for screening DNA-encoded small-molecule libraries inside living cells. The technology is designed to accelerate and improve the success rate for discovering novel, high-quality small molecules against protein targets of interest, including challenging targets that are difficult to express and purify in an active form.

“We are looking forward to the partnership with Vipergen and to building on its new technology for screening DNA-encoded libraries under physiologically relevant conditions of living cells for the development of new products in health and agriculture,” said Monika Lessl, SVP and Head of Corporate R&D and Social Innovation at Bayer.

“We are very pleased to partner with Bayer, a life sciences leader in human health and agriculture,” said Nils Hansen, PhD, Chief Executive Officer of Vipergen. “We look forward to applying our Cellular Binder Trap Enrichment® technology to screen DNA-encoded libraries in living cells to support the development of new drugs and sustainable crop-protection solutions.”

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Contact
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com

Vipergen Establishes Research Partnership with Aligos Therapeutics Focused on DNA Encoded Library (DEL)-Based Drug Discovery for Viral Infections and Liver Diseases

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with Aligos Therapeutics, Inc. (Nasdaq: ALGS). Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected Aligos protein targets. Aligos will select hits for development into novel therapeutics for viral and liver diseases. Aligos will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.

“We are delighted to collaborate with Aligos’ highly experienced team in its mission to develop best-in-class therapies that improve treatment outcomes in chronic hepatitis B, NASH, and coronavirus,” said Nils Hansen, PhD, Chief Executive Officer of Vipergen. “We look forward to applying our suite of DEL technologies to discover novel leads that help expand Aligos’ portfolio of differentiated drug candidates that target these significant unmet medical needs.”

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Contact:
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com

Vipergen Establishes Research Partnership with ALK Focused on DNA-Encoded Library (DEL)-Based Drug Discovery for Allergy Immunotherapies

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with the allergy company ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF). Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected ALK protein targets. ALK will select hits for development into novel therapeutics for the prevention and treatment of a broad range of allergies. ALK will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.

“Over the past century, ALK has pioneered many of the world’s leading technology advancements and product innovations for allergy and its treatment,” said Nils Hansen, PhD, Chief Executive Officer of Vipergen. “We look forward to applying our suite of DEL technologies, in partnership with ALK’s talented team, to discover leads to new or historically challenging allergy targets for development into potential new allergy immunotherapies.”

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Contact:
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com

BASF and Vipergen accelerate targeted research and development of sustainable crop protection products

Farmers worldwide are facing the challenge of feeding a growing population while reducing the impact of agriculture on the environment. BASF partners with Vipergen, a global leader in research services, to apply their technology to discover new active ingredients for sustainable crop protection products more efficiently and quickly.
For the first time in the agricultural sector, the research collaboration uses a technology from Vipergen that has already been applied successfully in the search for pharmaceutical active ingredients. This new technology allows for the testing of novel chemical compounds on target proteins in living cells. Tests in cells lead to more accurate results compared to conventional methods, which use target proteins previously isolated from cells and purified in an elaborate process. Testing can be performed on several million compounds, looking at their uses in crop protection as well as their environmental impact, all in a single experiment and in considerably shorter time. Promising compounds can be easily identified through a specific DNA coding. This targeted research approach can greatly accelerate the identification of new active ingredients.
“The collaboration with Vipergen will complement our set of tools aimed at developing novel, world-class, sustainable crop protection solutions for a connected offer that will benefit farmers, consumers and the environment,” said Juergen Huff, Senior Vice President, Research and Development Crop Protection at BASF Agricultural Solutions. “Through Vipergen’s powerful technology, we aim to identify active ingredients for new crop protection products more efficiently. This helps to accelerate the development of new solutions that increase agricultural productivity and reduce environmental impacts.”
“We are excited to partner with BASF to drive innovation for sustainable agriculture,” said Nils Hansen, Chief Executive Officer of Vipergen. “Applying our Cellular Binder Trap Enrichment® technology to screen DNA-encoded libraries in living cells will quickly provide high-quality hits that BASF can use to develop new sustainable crop protection products.”
BASF retains exclusive rights to globally commercialize all products resulting from the collaboration. Financial details of the partnership were not disclosed.

About BASF’s Agricultural Solutions division

With a rapidly growing population, the world is increasingly dependent on our ability to develop and maintain sustainable agriculture and healthy environments. Working with farmers, agricultural professionals, pest management experts and others, it is our role to help make this possible. That’s why we invest in a strong R&D pipeline and broad portfolio, including seeds and traits, chemical and biological crop protection, soil management, plant health, pest control and digital farming. With expert teams in the lab, field, office and in production, we connect innovative thinking and down-to-earth action to create real world ideas that work – for farmers, society and the planet. In 2020, our division generated sales of €7.7 billion. For more information, please visit www.agriculture.basf.com or any of our social media channels.

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Media Relations
BASF Agricultural Solutions
Alexandra Goeke
Phone: +49 174 3198080
alexandra.goeke@basf.com

Media Relations
Vipergen
Mary Moynihan
Phone: +1 802 9519600
mary@m2friend.com

Vipergen Establishes Research Partnership with PhoreMost Focused on DNA Encoded Library (DEL)-Based Drug Discovery

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with PhoreMost. Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected PhoreMost protein targets. PhoreMost will select hits for development into novel therapeutics for oncology. PhoreMost will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.

“Applying Vipergen’s suite of leading technologies for DNA-encoded library synthesis and screening, we aim to optimize our success rate for discovering novel, high-quality small drug molecules for several oncology targets that were previously considered undruggable,” said Rich Boyce, Vice President of Drug Discovery at PhoreMost. “We look forward to collaborating with the Vipergen team in our mission to deliver a diverse range of more effective and safe therapies for cancer patients.”

“We are delighted to partner with PhoreMost in its unique mission to develop a pipeline of transformative new therapies for cancer patients by identifying novel drug molecules for binding sites that have eluded conventional target discovery,” said Nils Hansen, PhD, Chief Executive Officer of Vipergen. “In particular, Vipergen’s newest platform—which enables screening DNA-encoded small-molecule libraries inside living cells, under physiologically relevant conditions—significantly expands our ability to discover novel small molecules against challenging targets.”

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Contact:
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com

Vipergen Establishes Partnership with Anavo Therapeutics to Support Phosphatase-Targeted Discovery Programs

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a drug discovery service agreement with Anavo Therapeutics. Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library (DEL) technology platforms to provide novel small-molecule drug leads against selected Anavo discovery targets. Financial details of the agreement were not disclosed.

“Vipergen’s innovative solutions to DNA-encoded libraries are valuable components for ramping up our proprietary drug discovery efforts against a selected portfolio of innovative targets,” said Birgit Zech, PhD, Chief Executive Officer of Anavo. “We look forward to partnering with Vipergen to jump-start Anavo’s proprietary drug development efforts as we continue to build a robust and reliable platform for phosphatase drug discovery against all valuable targets in the space.”

“We are excited to be selected by Anavo, a new company focused on unlocking the full therapeutic potential of human phosphatase biology to develop new cancer treatments,” said Nils Hansen, PhD, Chief Executive Officer of Vipergen. “Phosphatases are a rich target space that has been considered undruggable for decades. We look forward to applying our DNA-encoded library technologies to rapidly deliver high-quality hits and leads as part of Anavo’s systematic approach to discovering and developing small-molecule modulators of phosphatase activity.”

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

Contact:
Mary Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com